DE60310564T2 - Injizierbare depotformulierung enthaltend iloperidonkrystalle - Google Patents
Injizierbare depotformulierung enthaltend iloperidonkrystalle Download PDFInfo
- Publication number
- DE60310564T2 DE60310564T2 DE60310564T DE60310564T DE60310564T2 DE 60310564 T2 DE60310564 T2 DE 60310564T2 DE 60310564 T DE60310564 T DE 60310564T DE 60310564 T DE60310564 T DE 60310564T DE 60310564 T2 DE60310564 T2 DE 60310564T2
- Authority
- DE
- Germany
- Prior art keywords
- crystals
- depot formulation
- formulation according
- iloperidone
- value
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000013078 crystal Substances 0.000 title claims abstract description 92
- 239000000203 mixture Substances 0.000 title claims abstract description 70
- 238000009472 formulation Methods 0.000 title claims abstract description 65
- XMXHEBAFVSFQEX-UHFFFAOYSA-N iloperidone Chemical compound COC1=CC(C(C)=O)=CC=C1OCCCN1CCC(C=2C3=CC=C(F)C=C3ON=2)CC1 XMXHEBAFVSFQEX-UHFFFAOYSA-N 0.000 title claims abstract description 52
- 229960003162 iloperidone Drugs 0.000 title claims abstract description 49
- VIQCGTZFEYDQMR-UHFFFAOYSA-N fluphenazine decanoate Chemical compound C1CN(CCOC(=O)CCCCCCCCC)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 VIQCGTZFEYDQMR-UHFFFAOYSA-N 0.000 title 1
- 239000002207 metabolite Substances 0.000 claims abstract description 21
- 239000000725 suspension Substances 0.000 claims description 14
- 150000003839 salts Chemical class 0.000 claims description 9
- 239000004094 surface-active agent Substances 0.000 claims description 9
- 239000002562 thickening agent Substances 0.000 claims description 9
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 8
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 7
- 229930195725 Mannitol Natural products 0.000 claims description 7
- 239000004615 ingredient Substances 0.000 claims description 7
- 239000000594 mannitol Substances 0.000 claims description 7
- 235000010355 mannitol Nutrition 0.000 claims description 7
- 239000012453 solvate Substances 0.000 claims description 7
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 6
- 239000000194 fatty acid Substances 0.000 claims description 6
- 229930195729 fatty acid Natural products 0.000 claims description 6
- 238000002347 injection Methods 0.000 claims description 5
- 239000007924 injection Substances 0.000 claims description 5
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 5
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 5
- -1 sorbitan fatty acid esters Chemical class 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical class CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 3
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Polymers FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- 229920002785 Croscarmellose sodium Polymers 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- 239000000872 buffer Substances 0.000 claims description 2
- RKTYLMNFRDHKIL-UHFFFAOYSA-N copper;5,10,15,20-tetraphenylporphyrin-22,24-diide Chemical compound [Cu+2].C1=CC(C(=C2C=CC([N-]2)=C(C=2C=CC=CC=2)C=2C=CC(N=2)=C(C=2C=CC=CC=2)C2=CC=C3[N-]2)C=2C=CC=CC=2)=NC1=C3C1=CC=CC=C1 RKTYLMNFRDHKIL-UHFFFAOYSA-N 0.000 claims description 2
- 239000008121 dextrose Substances 0.000 claims description 2
- 239000002270 dispersing agent Substances 0.000 claims description 2
- 239000003995 emulsifying agent Substances 0.000 claims description 2
- 239000003925 fat Substances 0.000 claims description 2
- 150000002191 fatty alcohols Chemical class 0.000 claims description 2
- 239000000945 filler Substances 0.000 claims description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 2
- 239000008101 lactose Substances 0.000 claims description 2
- 239000000314 lubricant Substances 0.000 claims description 2
- 239000003755 preservative agent Substances 0.000 claims description 2
- 239000011780 sodium chloride Substances 0.000 claims description 2
- 239000003381 stabilizer Substances 0.000 claims description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims 1
- 239000011575 calcium Substances 0.000 claims 1
- 229910052791 calcium Inorganic materials 0.000 claims 1
- 235000001465 calcium Nutrition 0.000 claims 1
- 239000007859 condensation product Substances 0.000 claims 1
- 239000003906 humectant Substances 0.000 claims 1
- 238000009923 sugaring Methods 0.000 claims 1
- 239000002245 particle Substances 0.000 abstract description 10
- 230000002596 correlated effect Effects 0.000 abstract description 7
- 238000010521 absorption reaction Methods 0.000 abstract description 4
- 238000003801 milling Methods 0.000 abstract description 4
- 238000003860 storage Methods 0.000 abstract description 3
- 238000012414 sterilization procedure Methods 0.000 abstract 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 13
- 238000000034 method Methods 0.000 description 8
- 229920001983 poloxamer Polymers 0.000 description 6
- 230000036470 plasma concentration Effects 0.000 description 5
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 4
- 239000003708 ampul Substances 0.000 description 4
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000013270 controlled release Methods 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 230000008025 crystallization Effects 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 238000000227 grinding Methods 0.000 description 3
- 201000000980 schizophrenia Diseases 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000012065 filter cake Substances 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 239000004005 microsphere Substances 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 0 CC*Oc1cc(*)ccc1OCCCN(CC1)CCC1c1n[o]c2cc(*)ccc12 Chemical compound CC*Oc1cc(*)ccc1OCCCN(CC1)CCC1c1n[o]c2cc(*)ccc12 0.000 description 1
- ABSFVUWUFHLXKB-UHFFFAOYSA-N CCOOc1cc(C(N)=O)ccc1OCCCC(CCC1)CCC1c1n[o]c2c1ccc(C)c2 Chemical compound CCOOc1cc(C(N)=O)ccc1OCCCC(CCC1)CCC1c1n[o]c2c1ccc(C)c2 ABSFVUWUFHLXKB-UHFFFAOYSA-N 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 241000978776 Senegalia senegal Species 0.000 description 1
- 239000004147 Sorbitan trioleate Substances 0.000 description 1
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 239000005415 artificial ingredient Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 125000004284 isoxazol-3-yl group Chemical group [H]C1=C([H])C(*)=NO1 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 239000003488 releasing hormone Substances 0.000 description 1
- 235000019337 sorbitan trioleate Nutrition 0.000 description 1
- 229960000391 sorbitan trioleate Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Inorganic Chemistry (AREA)
- Psychiatry (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0216416.8A GB0216416D0 (en) | 2002-07-15 | 2002-07-15 | Organic compounds |
| GB0216416 | 2002-07-15 | ||
| PCT/EP2003/007619 WO2004006886A2 (en) | 2002-07-15 | 2003-07-14 | Injectable depot formulation comprising crystals of iloperidone |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE60310564D1 DE60310564D1 (de) | 2007-02-01 |
| DE60310564T2 true DE60310564T2 (de) | 2007-10-04 |
Family
ID=9940486
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60310564T Expired - Lifetime DE60310564T2 (de) | 2002-07-15 | 2003-07-14 | Injizierbare depotformulierung enthaltend iloperidonkrystalle |
Country Status (15)
| Country | Link |
|---|---|
| US (5) | US20050250813A1 (https=) |
| EP (1) | EP1523335B1 (https=) |
| JP (2) | JP5392961B2 (https=) |
| AT (1) | ATE348635T1 (https=) |
| AU (1) | AU2003281154B2 (https=) |
| CA (1) | CA2492467C (https=) |
| CY (1) | CY1106305T1 (https=) |
| DE (1) | DE60310564T2 (https=) |
| DK (1) | DK1523335T3 (https=) |
| ES (1) | ES2279153T3 (https=) |
| GB (1) | GB0216416D0 (https=) |
| NZ (1) | NZ537598A (https=) |
| PT (1) | PT1523335E (https=) |
| WO (1) | WO2004006886A2 (https=) |
| ZA (1) | ZA200410323B (https=) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2436439T3 (es) | 2001-10-30 | 2014-01-02 | Novartis Ag | Formulaciones de medicamento de liberación lenta de iloperidona con un polímero |
| GB0216416D0 (en) * | 2002-07-15 | 2002-08-21 | Novartis Ag | Organic compounds |
| ATE411797T2 (de) | 2003-10-23 | 2008-11-15 | Otsuka Pharma Co Ltd | Sterile injizierbare aripiprazol-formulierung mit kontrollierter freisetzung und verfahren |
| EP1799865B1 (en) | 2004-09-30 | 2012-06-06 | Vanda Pharmaceuticals Inc. | Methods for the administration of iloperidone |
| US20100063093A1 (en) | 2007-03-28 | 2010-03-11 | Curt Wolfgang | Methods for the administration of iloperidone |
| US20090306137A1 (en) | 2006-05-22 | 2009-12-10 | Wolfgang Curt D | Treatment for depressive disorders |
| US8198305B2 (en) | 2007-04-13 | 2012-06-12 | Concert Pharmaceuticals Inc. | 1,2-benzisoxazol-3-yl compounds |
| MY152789A (en) | 2007-07-31 | 2014-11-28 | Otsuka Pharma Co Ltd | Methods for producing aripiprazole suspension and freeze-dried formulation |
| EP2198048A2 (en) | 2007-09-10 | 2010-06-23 | Vanda Pharmaceuticals Inc. | Prediction of qt prolongation based on snp genotype |
| BRPI0820993A2 (pt) | 2007-12-13 | 2017-05-09 | Vanda Pharmaceuticals Inc | método e composição para tratar uma condição mediada por alfa adrenoceptor |
| SI2222300T1 (sl) | 2007-12-13 | 2014-11-28 | Vanda Pharmaceuticals Inc. | Postopek in sestavek za zdravljenje stanja, posredovanega z receptorjem serotonina |
| WO2010031497A1 (en) * | 2008-09-19 | 2010-03-25 | Miklos Vertessy | New process for the preparation of iloperidone |
| CN101822673B (zh) * | 2009-03-04 | 2013-09-18 | 北京德众万全药物技术开发有限公司 | 一种含有伊潘立酮的固体药物组合物 |
| US20120136050A1 (en) | 2009-07-16 | 2012-05-31 | Vanda Pharmaceuticals Inc. | Use of a melatonin agonist for the treatment of sleep disorders including primary insomnia |
| EP2479176B1 (en) * | 2009-09-19 | 2014-09-17 | Zhejiang Huahai Pharmaceutical Co., Ltd. | Method for preparation of iloperidone and crystallization method thereof |
| CN102030744B (zh) * | 2009-09-30 | 2013-04-17 | 天津药物研究院 | 伊潘立酮晶体、其制备方法及药物组合物 |
| WO2011055188A1 (en) * | 2009-11-05 | 2011-05-12 | Orchid Chemicals And Pharmaceuticals Limited | An improved process for the preparation of iloperidone |
| MX2012007365A (es) * | 2009-12-23 | 2012-08-15 | Lupin Ltd | Composiciones farmaceuticas de liberacion lenta de iloperidona. |
| CN102108081A (zh) * | 2009-12-25 | 2011-06-29 | 重庆医药工业研究院有限责任公司 | 伊潘立酮的新晶型及其制备方法 |
| LT2523669T (lt) | 2010-01-11 | 2017-04-25 | Inotek Pharmaceuticals Corporation | Akispūdžio mažinimo būdas, derinys ir rinkinys |
| PH12012501906A1 (en) | 2010-03-26 | 2013-01-14 | Inotek Pharmaceuticals Corp | Method of reducing intraocular pressure in humans using n6 -cyclopentyladenosine (cpa), cpa derivatives or prodrugs thereof |
| CN101822674B (zh) * | 2010-05-27 | 2015-03-11 | 北京德众万全医药科技有限公司 | 一种伊潘立酮药物组合物及其制备方法 |
| JP5893616B2 (ja) * | 2010-10-18 | 2016-03-23 | 大日本住友製薬株式会社 | 注射用徐放性製剤 |
| WO2012063269A2 (en) | 2010-11-12 | 2012-05-18 | Cadila Healthcare Limited | Process for preparing iloperidone |
| WO2012090138A1 (en) | 2010-12-27 | 2012-07-05 | Ranbaxy Laboratories Limited | Processes for the preparation of iloperidone |
| CN102680636A (zh) * | 2011-03-11 | 2012-09-19 | 天津药物研究院 | 一种伊潘立酮原料药及其中间体的质量控制方法 |
| US11918557B2 (en) | 2012-01-26 | 2024-03-05 | Vanda Pharmaceuticals Inc. | Treatment of circadian rhythm disorders |
| WO2013112951A2 (en) | 2012-01-26 | 2013-08-01 | Vanda Pharmaceuticals Inc. | Treatment of circadian rhythm disorders |
| PT2807178T (pt) | 2012-01-26 | 2017-08-08 | Inotek Pharmaceuticals Corp | Polimorfos anidros de nitrato de (2r,3s,4r,5r)-5-(6-(ciclopentilamino)-9h-purin-9-il)-3,4-dihidroxitetrahidrofuran-2-il)}metilo e seus processos de preparação |
| CN102659771B (zh) * | 2012-04-18 | 2013-11-27 | 吉林三善恩科技开发有限公司 | 一种伊潘立酮药物共晶及其制备方法 |
| CN102633786B (zh) * | 2012-04-18 | 2013-11-27 | 吉林三善恩科技开发有限公司 | 一种伊潘立酮药物共晶及其制备方法 |
| BR112014028446A2 (pt) | 2012-05-18 | 2017-10-24 | Vanda Pharmaceuticals Inc | composto isolado, composição farmacêutica, método de tratamento ou prevenção de pelo menos um de doenças, distúrbios ou condições seguintes, e, método de tratamento ou prevenção de um distúrbio de ritmo circadiano ou distúrbio com um componente circadiano em um indivíduo |
| KR102148990B1 (ko) | 2012-12-18 | 2020-08-27 | 반다 파마슈티칼즈, 인코퍼레이티드. | 일주기 리듬 장애의 치료 |
| NZ630759A (en) | 2013-03-15 | 2017-07-28 | Inotek Pharmaceuticals Corp | Ophthalmic formulations comprising an a1 agonist |
| US11090285B2 (en) | 2013-11-12 | 2021-08-17 | Vanda Pharmaceuticals Inc | Treatment of circadian rhythm disorders |
| US10376487B2 (en) | 2013-11-12 | 2019-08-13 | Vanda Pharmaceuticals Inc. | Method of treatment |
| CN103599074A (zh) * | 2013-11-26 | 2014-02-26 | 重庆医药工业研究院有限责任公司 | 一种伊潘立酮缓释微球及其制备方法 |
| WO2016134049A1 (en) | 2015-02-17 | 2016-08-25 | Vanda Pharmaceuticals Inc. | Iloperidone for the treatment of schizophrenia |
| US11071728B2 (en) | 2015-12-11 | 2021-07-27 | Vanda Pharmaceuticals Inc. | Treatment of schizophrenia |
| CN106831741B (zh) * | 2016-12-28 | 2019-08-23 | 北京医药集团有限责任公司 | 一种伊潘立酮超细粉体的制备方法 |
| US10935106B2 (en) * | 2018-06-14 | 2021-03-02 | Serapid, Inc. | Block chain with monolithic links |
| CN113164382A (zh) * | 2018-12-04 | 2021-07-23 | 万达制药公司 | 伊潘立酮的贮库施用 |
| US20200171018A1 (en) * | 2018-12-04 | 2020-06-04 | Vanda Pharmaceuticals Inc. | Depot administration of iloperidone |
| US11607408B2 (en) | 2019-10-15 | 2023-03-21 | Vanda Pharmaceuticals Inc. | Method of treatment of schizophrenia |
| WO2024137439A1 (en) | 2022-12-19 | 2024-06-27 | Vanda Pharmaceuticals Inc. | Dosage regime of iloperidone for treating bipolar i disorder and schizophrenia |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB216416A (en) | 1923-09-06 | 1924-05-29 | James Baker And Sons Ltd | Improvements in boots and shoes |
| IT1093097B (it) * | 1976-10-28 | 1985-07-19 | Hoechst France | Acidi n-carbetossi(alfa-amminofenilacetici)otticamente attivi relativo procedimento di produzione e loro impiego per la produzione di acidi alfa-ammino-fenilacetici otticamente attivi corrispondenti |
| CH656884A5 (de) | 1983-08-26 | 1986-07-31 | Sandoz Ag | Polyolester, deren herstellung und verwendung. |
| DE3345355A1 (de) * | 1983-12-15 | 1985-06-27 | Hoechst Ag, 6230 Frankfurt | Verfahren zur racematspaltung bicyclischer imino-(alpha)-carbonsaeureester |
| DE3511587A1 (de) | 1985-03-27 | 1986-10-02 | Schering AG, Berlin und Bergkamen, 1000 Berlin | Glykoester des estradiols und estriols |
| US4886370A (en) | 1987-08-25 | 1989-12-12 | Nkk Corporation | Method for detecting a state of substance existing in pipe |
| US5364866A (en) * | 1989-05-19 | 1994-11-15 | Hoechst-Roussel Pharmaceuticals, Inc. | Heteroarylpiperidines, pyrrolidines and piperazines and their use as antipsychotics and analetics |
| US5776963A (en) * | 1989-05-19 | 1998-07-07 | Hoechst Marion Roussel, Inc. | 3-(heteroaryl)-1- (2,3-dihydro-1h-isoindol-2-yl)alkyl!pyrrolidines and 3-(heteroaryl)-1- (2,3-dihydro-1h-indol-1-yl)alkyl!pyrrolidines and related compounds and their therapeutic untility |
| ES2076253T3 (es) * | 1989-05-19 | 1995-11-01 | Hoechst Roussel Pharma | N-(ariloxialquil)-heteroarilpiperidinas y -heteroarilpiperazinas, un procedimiento para su preparacion y su uso como medicamentos. |
| US5538739A (en) * | 1989-07-07 | 1996-07-23 | Sandoz Ltd. | Sustained release formulations of water soluble peptides |
| WO1991018927A1 (en) * | 1990-06-04 | 1991-12-12 | Schering Corporation | Method for preparing interferon alpha-2 crystals |
| CA2095499A1 (en) * | 1992-05-08 | 1993-11-09 | Petrus J. M. Van Den Oetelaar | Depot preparation |
| CA2148823C (en) | 1992-11-17 | 1999-03-09 | Welfide Corporation | Sustained release microsphere preparation containing antipsychotic drug and production process thereof |
| CN1074923C (zh) | 1993-11-19 | 2001-11-21 | 詹森药业有限公司 | 微囊密封的3-哌啶基取代的1,2-苯并异唑类和1,2-苯并异噻唑类 |
| US5902882A (en) * | 1996-04-17 | 1999-05-11 | Hoffmann-La Roche Inc. | Assymetric synthesis of azepines |
| TW487572B (en) * | 1996-05-20 | 2002-05-21 | Janssen Pharmaceutica Nv | Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters |
| PL337027A1 (en) * | 1997-05-26 | 2000-07-31 | Akzo Nobel Nv | Salts of aromatic sulphonic acids |
| UA72189C2 (uk) * | 1997-11-17 | 2005-02-15 | Янссен Фармацевтика Н.В. | Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот |
| US5955459A (en) * | 1997-11-26 | 1999-09-21 | Neuromedica, Inc. | Fatty acid-antipsychotic compositions and uses thereof |
| US6541606B2 (en) * | 1997-12-31 | 2003-04-01 | Altus Biologics Inc. | Stabilized protein crystals formulations containing them and methods of making them |
| DE19816070A1 (de) | 1998-04-09 | 1999-10-14 | Aventis Res & Tech Gmbh & Co | Retardtablette hergestellt aus linearen wasserunlöslichen Polysacchariden |
| PL348107A1 (en) | 1998-10-16 | 2002-05-06 | Janssen Pharmaceutica Nv | Therapy for improving cognition |
| US6509310B1 (en) | 2000-06-01 | 2003-01-21 | Huish Detergents, Inc. | Compositions containing α-sulfofatty acid esters and method of making the same |
| AU2001263775A1 (en) | 2000-06-02 | 2001-12-11 | Novo-Nordisk A/S | Glucose dependent release of insulin from glucose sensing insulin derivatives |
| DK1425272T3 (da) * | 2001-08-31 | 2011-11-21 | Novartis Ag | Optiske isomerer af en iloperidon-metabolit |
| ES2436439T3 (es) * | 2001-10-30 | 2014-01-02 | Novartis Ag | Formulaciones de medicamento de liberación lenta de iloperidona con un polímero |
| GB0216416D0 (en) | 2002-07-15 | 2002-08-21 | Novartis Ag | Organic compounds |
-
2002
- 2002-07-15 GB GBGB0216416.8A patent/GB0216416D0/en not_active Ceased
-
2003
- 2003-07-14 AU AU2003281154A patent/AU2003281154B2/en not_active Expired
- 2003-07-14 WO PCT/EP2003/007619 patent/WO2004006886A2/en not_active Ceased
- 2003-07-14 EP EP03756455A patent/EP1523335B1/en not_active Expired - Lifetime
- 2003-07-14 PT PT03756455T patent/PT1523335E/pt unknown
- 2003-07-14 AT AT03756455T patent/ATE348635T1/de active
- 2003-07-14 CA CA2492467A patent/CA2492467C/en not_active Expired - Lifetime
- 2003-07-14 DE DE60310564T patent/DE60310564T2/de not_active Expired - Lifetime
- 2003-07-14 ES ES03756455T patent/ES2279153T3/es not_active Expired - Lifetime
- 2003-07-14 US US10/521,064 patent/US20050250813A1/en not_active Abandoned
- 2003-07-14 DK DK03756455T patent/DK1523335T3/da active
- 2003-07-14 NZ NZ537598A patent/NZ537598A/en not_active IP Right Cessation
- 2003-07-14 JP JP2004520629A patent/JP5392961B2/ja not_active Expired - Lifetime
-
2004
- 2004-12-22 ZA ZA200410323A patent/ZA200410323B/en unknown
-
2006
- 2006-12-29 CY CY20061101867T patent/CY1106305T1/el unknown
-
2008
- 2008-10-21 US US12/254,925 patent/US20090099232A1/en not_active Abandoned
-
2010
- 2010-10-21 JP JP2010236087A patent/JP5670698B2/ja not_active Expired - Lifetime
-
2011
- 2011-05-12 US US13/106,417 patent/US8293765B2/en not_active Expired - Fee Related
-
2012
- 2012-02-21 US US13/401,310 patent/US8227488B2/en not_active Expired - Fee Related
- 2012-09-14 US US13/618,753 patent/US8614232B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| DK1523335T3 (da) | 2007-01-29 |
| WO2004006886A3 (en) | 2004-02-19 |
| US20120156264A1 (en) | 2012-06-21 |
| ES2279153T3 (es) | 2007-08-16 |
| ATE348635T1 (de) | 2007-01-15 |
| HK1076029A1 (en) | 2006-01-06 |
| JP2005533093A (ja) | 2005-11-04 |
| PT1523335E (pt) | 2007-02-28 |
| CA2492467A1 (en) | 2004-01-22 |
| US20110212141A1 (en) | 2011-09-01 |
| CY1106305T1 (el) | 2011-10-12 |
| EP1523335A2 (en) | 2005-04-20 |
| JP2011016849A (ja) | 2011-01-27 |
| WO2004006886A2 (en) | 2004-01-22 |
| NZ537598A (en) | 2006-07-28 |
| JP5392961B2 (ja) | 2014-01-22 |
| EP1523335B1 (en) | 2006-12-20 |
| JP5670698B2 (ja) | 2015-02-18 |
| AU2003281154A1 (en) | 2004-02-02 |
| ZA200410323B (en) | 2006-06-28 |
| US8614232B2 (en) | 2013-12-24 |
| US20090099232A1 (en) | 2009-04-16 |
| US8293765B2 (en) | 2012-10-23 |
| GB0216416D0 (en) | 2002-08-21 |
| DE60310564D1 (de) | 2007-02-01 |
| US8227488B2 (en) | 2012-07-24 |
| CA2492467C (en) | 2010-03-16 |
| AU2003281154B2 (en) | 2006-10-12 |
| US20130012542A1 (en) | 2013-01-10 |
| US20050250813A1 (en) | 2005-11-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60310564T2 (de) | Injizierbare depotformulierung enthaltend iloperidonkrystalle | |
| DE69829286T2 (de) | Neues verfahren zur herstellung von paroxetin enthaltenden festen dispersionen | |
| EP2785691B1 (en) | Donepezil pamoate, preparation method and its use | |
| DE69408666T2 (de) | Risperidon pamoate | |
| KR100358373B1 (ko) | 9-하이드록시리스페리돈지방산에스테르의수성현탁액 | |
| DE602005001833T2 (de) | Zusammensetzungen enthaltend Ecteinascidin und einen Disaccharide | |
| DE69722401T2 (de) | Kombinationen von vasopressin und adrenergischen wirkstoffen zur behandlung des plötzlichen herztods | |
| KR20220044921A (ko) | 리바스티그민을 포함하는 장기지속형 제제 및 이의 제조방법 | |
| US12433887B2 (en) | Aripiprazole injectable suspension formulation having prolonged shelf life | |
| DE69625877T2 (de) | Verwendung von 5-HT1A Rezeptor-Liganden zur Behandlung des Glaukoms | |
| DE69426062T2 (de) | Zusammensetzungen von ergolinderivaten zur behandlung des glaukoms | |
| DE60225694T2 (de) | Neues polymorph von fexo-fenadin | |
| DE202007019385U1 (de) | Pharmazeutische Zusammensetzungen, umfassend Clopidogrel | |
| TW202504607A (zh) | 羅哌卡因或其藥學上可接受的鹽的組合物及其用途 | |
| EP2142169B1 (de) | Wässrige pharmazeutische zubereitung | |
| DE60020814T2 (de) | Zolpidem salze | |
| HK1076029B (en) | Injectable depot formulation comprising crystals of iloperidone |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8363 | Opposition against the patent |